This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary PDGFRα/β Therapeutic Antibody Development
Background of PDGFRα/β
Due to their crucial roles in cell proliferation and migration in companion animals, PDGFRα and PDGFRβ have become targets for various therapeutic strategies, especially in tumor treatment. BioVenic offers veterinary PDGFRα/β therapeutic antibody development services, assisting in the advancement of veterinary PDGFRα/β therapeutic antibodies and exploring their potential in treating companion animal diseases through comprehensive process coverage.
Background of PDGFRα/β
| Full Name | Platelet derived growth factor receptor alpha/beta |
|---|---|
| Aliases | CD140A, PDGFR2, PDGFR-2, PDGFRA, PDGFRα/ CD140B, IBGC4, IMF1, JTK12, KOGS, PDGFR1, PDGFR-1, PDGFRB, PDGFRβ, PENTT. |
| Target Profile | As tyrosine kinase receptors on the cell surface, PDGFRα and PDGFRβ become parts of the cytokine receptor superfamily. They are activated by binding ligands from PDGF family and play roles in proliferation, migration, differentiation, and survival processes in various cell types such as endothelial cells, fibroblasts, and vascular smooth muscle cells. Abnormal expression and activation of PDGFR are also associated with the growth, development, and microenvironment regulation of tumors. |
MoA of PDGFRα/β
Both PDGFRα and PDGFRβ are involved in several well-characterized signaling pathways, such as Ras/MAPK, PI3K, and PLC-γ. PDGFR primarily connects to the Ras/MAPK pathway through adaptor proteins Grb2 and Shc. Grb2 binds to the activated PDGFR via its SH2 domain and complexes with Sos1 via its SH3 domain. Sos1, in turn, activates Ras, leading to downstream activation of Raf-1 and the MAPK cascade. MAPK signaling activates gene transcription, stimulating cell growth, differentiation, and migration. PDGFR also activates the PI3K pathway, promoting actin reorganization, directed cell movement, stimulation of cell growth, and inhibition of apoptosis. PLC-γ binds to PDGFR, leading to intracellular calcium mobilization and PKC activation through phosphorylation, stimulating cell growth and movement. PDGFR also interacts with integrins, enhancing cell proliferation, migration, and survival.
Fig.1 Simplified depiction of receptor interactions: PDGFR-α and PDGFR-β crosstalk with cadherin-11, and β-catenin's interaction with ERK through DUSP1 inhibitor. 1,2
Application in Veterinary Therapeutics
Overexpression of PDGFRα/β has been studied in various companion animal tumors, including canine mast cell tumors, astrocytomas, lymphomas, osteosarcomas, sac adenocarcinomas, thyroid carcinomas, hemangiosarcomas, cutaneous peripheral nerve sheath tumors, and mammary tumors. This highlights the importance of PDGFRα/β in animal tumor biology, as its role in angiogenesis, promoting cancer development, and potential invasiveness. Inhibition of PDGFR has also shown significant therapeutic effects in feline injection site sarcomas, and PDGFRβ expression is found in most feline histiocytic diseases. Therefore, considering the use of PDGFRα/β therapeutic antibodies for inhibiting PDGFRα/β could have desired therapeutic effects in various canine and feline tumors as well as other related diseases.
Veterinary PDGFRα/β Therapeutic Antibody Development Services
PDGFRα/β is involved in companion animal tumor cell differentiation, invasion, and angiogenesis, making them the target for therapeutic antibody development for treatment. BioVenic has established a platform for the development of veterinary PDGFRα/β therapeutic antibodies. Leveraging extensive antibody preparation experience, we use hybridoma, single B cell, and phage display techniques for the development of high-quality veterinary PDGFRα/β therapeutic antibodies. Additionally, we offer antibody characterization and engineering services, aiming to develop high-affinity and low-immunogenicity antibodies.
Please click the link below for more information about our veterinary PDGFRα/β therapeutic antibody development services.
Fig.2 Antibody discovery and production methods: from mouse hybridoma to transgenic mice. (BioVenic Original)
Why Choose Us?
Our one-stop veterinary therapeutic antibody development service covers the entire process, from animal immunization to antibody preparation, screening, and late-stage characterization and validation.
Our antibody engineering services include antibody caninization/felinization, affinity maturation, and Fc engineering, reducing immunogenicity for specific species, enhancing affinity, and extending the half-life of antibodies.
We provide species-specific antibody development services to improve compatibility and efficacy within specific species and reduce safety issues related to immunogenicity.
Therapeutics targeting PDGFRα/β have the potential to be developed for inhibiting the growth and angiogenesis of various companion animal tumors and treating certain fibrotic diseases. BioVenic offers veterinary PDGFRα/β therapeutic antibody development services. Our services cover the entire development process, meeting your needs at each development stage. If you require development of veterinary PDGFRα/β therapeutic antibodies, please contact us immediately.
References
- Karagöz, Zeynep, et al. "Computational evidence for multi-layer crosstalk between the cadherin-11 and PDGFR pathways." Scientific Reports 13.1 (2023): 15804.
- Image retrieved from Figure 1 "The schematic representation of receptor level crosstalk between growth factor receptors (PDGFR-α and PDGFR-β) and cadherin-11, and the proposed crosstalk between β-catenin and ERK via the ERK inhibitor DUSP1." Karagöz, Zeynep, et al., 2023, used under [CC BY 4.0], the image title was changed to "Simplified depiction of receptor interactions: PDGFR-α and PDGFR-β crosstalk with cadherin-11, and β-catenin's interaction with ERK through DUSP1 inhibitor."